Data / New clinical trials / Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms trials: 236 new

Name: New Triple Negative Breast Neoplasms clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Triple Negative Breast Neoplasms clinical trials: 236 rows for $11.80, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 10 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/triple-negative-breast-neoplasms, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 3, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

236 clinical studies in Triple Negative Breast Neoplasms were first posted on ClinicalTrials.gov from November 12, 2024 to November 3, 2026; 73 have an industry sponsor and 207 are recruiting or about to. The newest, NCT07914309, was posted on November 3, 2026: Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer (Washington University School of Medicine).

The request: Every new Triple Negative Breast Neoplasms clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

236New trials
73Industry sponsored
207Recruiting or not yet
November 3, 2026Latest posted

Newest trials

The newest 100 of 236, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 3, 2026	NCT07914309	Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer	Washington University School of Medicine	Phase 2	Not yet recruiting	Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer	17	United States	clinicaltrials.gov
October 27, 2026	NCT07899632	A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors	Medsyn Biopharma, LLC	Phase 1/2	Not yet recruiting	Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer...	75		clinicaltrials.gov
October 26, 2026	NCT07894874	A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.	InventisBio Yiqi Beijing Limited	Phase 1	Not yet recruiting	Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer	204		clinicaltrials.gov
October 21, 2026	NCT07884721	Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer	FASTEN	Not applicable	Not yet recruiting	Triple-Negative Breast Cancer (TNBC)	144	France	clinicaltrials.gov
October 20, 2026	NCT07884201	Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment	Fudan University	Phase 2	Not yet recruiting	Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy	572		clinicaltrials.gov
October 19, 2026	NCT07880600	Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer	Fujian Cancer Hospital	Observational	Recruiting	Breast Neoplasm Female, Triple -Negative Breast Cancer	120	China	clinicaltrials.gov
October 19, 2026	NCT07879911	A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or...	CSPC Megalith Biopharmaceutical Co.,Ltd.	Phase 3	Not yet recruiting	Triple Negative Breast Cancer	550		clinicaltrials.gov
October 15, 2026	NCT07876557	A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative...	Shanghai Junshi Bioscience Co., Ltd.	Phase 2	Recruiting	Triple-negative Breast Cancer	184	China	clinicaltrials.gov
October 9, 2026	NCT07867470	TROPION Breast Respond in 1L TNBC	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Observational	Not yet recruiting	Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer	400		clinicaltrials.gov
October 7, 2026	NCT07862751	US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving...	Emory University	Phase 2	Not yet recruiting	Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma	32	United States	clinicaltrials.gov
October 5, 2026	NCT07857486	Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer	Institut Paoli-Calmettes	Phase 2	Not yet recruiting	Early Triple-Negative Breast Cancer	84		clinicaltrials.gov
October 2, 2026	NCT07856225	Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer	Fundación Santa Fe de Bogota	Observational	Recruiting	Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer	370	Colombia	clinicaltrials.gov
September 29, 2026	NCT07847398	Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.	Centre Antoine Lacassagne	Not applicable	Not yet recruiting	Triple-negative Breast Cancer (TNBC), Stage II-III	50	France	clinicaltrials.gov
September 28, 2026	NCT07844473	Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer	King Faisal Specialist Hospital & Research Center	Not applicable	Recruiting	Breast Cancer With Low to Intermediate HER2 Expression, Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast...	35	Saudi Arabia	clinicaltrials.gov
September 22, 2026	NCT07833891	Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment	Assistance Publique - Hôpitaux de Paris	Observational	Not yet recruiting	Breast Cancer, Breast Cancer (Triple Negative Type)	500		clinicaltrials.gov
September 18, 2026	NCT07828652	Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer...	Yeon Hee Park	Observational	Not yet recruiting	TNBC - Triple-Negative Breast Cancer	2,000		clinicaltrials.gov
September 18, 2026	NCT07827079	A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Phase 2	Completed	Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy	36	China	clinicaltrials.gov
September 15, 2026	NCT07820228	Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy	Hellenic Cooperative Oncology Group	Observational	Completed	Triple Negative Breast Cancer	3,648	Greece	clinicaltrials.gov
September 8, 2026	NCT07808086	Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer	Istituti Clinici Scientifici Maugeri SpA	Observational	Recruiting	Breast Cancer	30	Italy	clinicaltrials.gov
September 3, 2026	NCT07801508	A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors	Novartis Pharmaceuticals	Phase 1	Recruiting	Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small...	66	Australia, Japan	clinicaltrials.gov
August 26, 2026	NCT07788222	Sacituzumab Govitecan and Q901 in Advanced TNBC	Yonsei University	Phase 2	Not yet recruiting	Triple Negative Breast Neoplasms	48		clinicaltrials.gov
August 26, 2026	NCT07786428	Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC	University of Texas Southwestern Medical Center	Phase 2	Not yet recruiting	Triple-Negative Breast Cancer (TNBC)	60	United States	clinicaltrials.gov
August 20, 2026	NCT07776951	Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast...	University of Milan	Not applicable	Recruiting	Breast Cancer	126	Italy	clinicaltrials.gov
August 17, 2026	NCT07768436	A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer	Memorial Sloan Kettering Cancer Center	Phase 2	Recruiting	Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer	76	United States	clinicaltrials.gov
August 13, 2026	NCT07762703	Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple...	BreakBio Corp	Phase 1/2	Not yet recruiting	Triple-Negative Breast Cancer (TNBC)	10	United States	clinicaltrials.gov
August 12, 2026	NCT07760844	An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC	Fudan University	Phase 3	Not yet recruiting	Breast Cancer, Triple Negative Breast Cancer (TNBC)	180		clinicaltrials.gov
August 7, 2026	NCT07752550	Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer	Harbin Medical University	Phase 2	Not yet recruiting	Triple-Negative Breast Cancer (TNBC)	120	China	clinicaltrials.gov
August 6, 2026	NCT07749586	A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors	Arvinas Inc.	Phase 1/2	Recruiting	Advanced Solid Tumor	499	United States	clinicaltrials.gov
August 4, 2026	NCT07743723	A Study of IOV-5001 in Adults With Advanced Solid Tumors	Iovance Biotherapeutics, Inc.	Phase 1/2	Not yet recruiting	Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and...	106	United States	clinicaltrials.gov
August 4, 2026	NCT07743632	Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC	University of Kansas Medical Center	Phase 2	Not yet recruiting	Breast Cancer, Triple Negative Breast Cancer	110		clinicaltrials.gov
August 3, 2026	NCT07743190	A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative...	Medical University of South Carolina	Phase 2	Recruiting	Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes	55	United States	clinicaltrials.gov
August 3, 2026	NCT07741968	A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer	City of Hope Medical Center	Not applicable	Recruiting	Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC...	126	United States	clinicaltrials.gov
July 31, 2026	NCT07739485	Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study	Liu Shu	Phase 1/2	Recruiting	Triple -Negative Breast Cancer	30	China	clinicaltrials.gov
July 28, 2026	NCT07730125	Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies	CoRegen, Inc.	Phase 1/2	Not yet recruiting	HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer	67		clinicaltrials.gov
July 28, 2026	NCT07729956	A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated...	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 3	Recruiting	Triple-Negative Breast Cancer (TNBC)	436	China	clinicaltrials.gov
July 23, 2026	NCT07723469	Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery	SURGE Therapeutics	Phase 3	Not yet recruiting	TNBC - Triple-Negative Breast Cancer	400	United States	clinicaltrials.gov
July 23, 2026	NCT07721259	A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden	University of Washington	Phase 2	Not yet recruiting	Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC...	60	United States	clinicaltrials.gov
July 20, 2026	NCT07714382	Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer	Sohag University	Observational	Completed	Triple-Negative Breast Cancer (TNBC)	100	Egypt	clinicaltrials.gov
July 15, 2026	NCT07705438	Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC	Fudan University	Observational	Recruiting	Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT	30	China	clinicaltrials.gov
July 15, 2026	NCT07705334	A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors	SHY Therapeutics	Phase 1	Recruiting	Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric...	30	United States	clinicaltrials.gov
July 13, 2026	NCT07698106	Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC	University Health Network, Toronto	Phase 1/2	Recruiting	Triple-Negative Breast Cancer (TNBC)	60	Canada	clinicaltrials.gov
July 7, 2026	NCT07687446	Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer	Assistance Publique - Hôpitaux de Paris	Observational	Not yet recruiting	Breast Cancer (Triple Negative Breast Cancer (TNBC))	100		clinicaltrials.gov
July 2, 2026	NCT07681297	Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and...	National University Hospital, Singapore	Phase 1/2	Not yet recruiting	Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer	154	Singapore	clinicaltrials.gov
July 1, 2026	NCT07679360	A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple...	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3	Recruiting	Triple Negative Breast Cancer	1,000	China	clinicaltrials.gov
June 29, 2026	NCT07672431	Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression	Barbara Ann Karmanos Cancer Institute	Not applicable	Not yet recruiting	Triple Negative Breast Cancer	24	United States	clinicaltrials.gov
June 26, 2026	NCT07671092	Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC	RayzeBio, Inc.	Early phase 1	Recruiting	Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2...	40	Australia, New Zealand, South Africa	clinicaltrials.gov
June 25, 2026	NCT07669610	An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC	Fudan University	Phase 3	Not yet recruiting	Breast Cancer, Triple Negative Breast Cancer (TNBC)	140		clinicaltrials.gov
June 23, 2026	NCT07662252	Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer	Federico II University	Observational	Not yet recruiting	Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2 + Breast Cancer	186		clinicaltrials.gov
June 17, 2026	NCT07652242	Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer	Immunomic Therapeutics, Inc.	Phase 1	Recruiting	Triple Negative Breast Cancer (TNBC)	60	United States	clinicaltrials.gov
June 12, 2026	NCT07646106	THE-0504 in Patients With Solid Tumors	Thena Biotech S.r.l.	Phase 1	Recruiting	Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer...	30	Italy	clinicaltrials.gov
June 10, 2026	NCT07638852	Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.	Fudan University	Phase 2	Recruiting	TNBC, Triple Negative Breast Cancer, Brain Metastasases	58	China	clinicaltrials.gov
June 5, 2026	NCT07630961	Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors	Novartis Pharmaceuticals	Phase 1	Recruiting	Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer...	66	Denmark, Japan	clinicaltrials.gov
June 3, 2026	NCT07623642	A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or...	GV20 Therapeutics	Phase 2	Not yet recruiting	Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and...	227	China	clinicaltrials.gov
June 3, 2026	NCT07623369	A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors	Huahui Health	Phase 1	Recruiting	Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell...	299	Australia, China	clinicaltrials.gov
June 2, 2026	NCT07619534	Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior...	National Cancer Institute (NCI)	Observational	Recruiting	Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast	139	United States	clinicaltrials.gov
May 28, 2026	NCT07610525	Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial	M.D. Anderson Cancer Center	Phase 2	Not yet recruiting	Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2	200	United States	clinicaltrials.gov
May 22, 2026	NCT07601178	QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With...	Jiangsu Cancer Institute & Hospital	Phase 2	Recruiting	TNBC, Triple Negative Breast Cancer	34	China	clinicaltrials.gov
May 19, 2026	NCT07597642	ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies...	IRCCS San Raffaele	Not applicable	Not yet recruiting	Breast Cancer Early Stage Breast Cancer (Stage 1-3)	55	Italy	clinicaltrials.gov
May 12, 2026	NCT07581314	Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)	Telomir Pharmaceuticals, Inc.	Phase 1/2	Not yet recruiting	Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer	76		clinicaltrials.gov
May 6, 2026	NCT07570524	Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer	Center Eugene Marquis	Observational	Recruiting	Triple-negative Breast Cancer (TNBC)	200	France	clinicaltrials.gov
April 29, 2026	NCT07556848	A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer	Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 3	Not yet recruiting	Locally Advanced or Metastatic Triple-negative Breast Cancer	356	China	clinicaltrials.gov
April 29, 2026	NCT07555210	Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy	Jessica Mezzanotte Sharpe	Not applicable	Recruiting	Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer)...	25	United States	clinicaltrials.gov
April 27, 2026	NCT07552181	Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast...	Yuan Yuan	Phase 2	Not yet recruiting	TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma	50	United States	clinicaltrials.gov
April 27, 2026	NCT07551765	Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and...	Barts & The London NHS Trust	Observational	Not yet recruiting	Triple Negative Breast Cancer (TNBC), Early Setting	300	United Kingdom	clinicaltrials.gov
April 24, 2026	NCT07551050	Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer	Fudan University	Observational	Recruiting	TNBC - Triple-Negative Breast Cancer	300	China	clinicaltrials.gov
April 23, 2026	NCT07546695	Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple...	University Hospital, Basel, Switzerland	Observational	Recruiting	Breast Cancer	600	Switzerland	clinicaltrials.gov
April 22, 2026	NCT07545122	A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative...	Context Therapeutics Inc.	Phase 1	Recruiting	Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer	162	Australia	clinicaltrials.gov
April 22, 2026	NCT07544056	A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer	BeBetter Med Inc	Phase 2/3	Recruiting	Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer	446	China	clinicaltrials.gov
April 17, 2026	NCT07536815	An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced...	CytoDyn, Inc.	Not applicable	Temporarily not available	TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer	Not listed	United States	clinicaltrials.gov
April 16, 2026	NCT07533123	A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard...	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Phase 3	Recruiting	Triple Negative Breast Cancer	364	China	clinicaltrials.gov
April 14, 2026	NCT07528768	HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.	The University of The West Indies	Phase 2	Not yet recruiting	Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer	750	Barbados, Ghana, Jamaica	clinicaltrials.gov
April 14, 2026	NCT07527819	Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)	Peter MacCallum Cancer Centre, Australia	Observational	Not yet recruiting	Triple Negative Breast Cancer (TNBC)	75	Australia	clinicaltrials.gov
April 13, 2026	NCT07525869	An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC...	Yonsei University	Not applicable	Recruiting	Triple-Negative Breast Cancer	40	South Korea	clinicaltrials.gov
April 13, 2026	NCT07523789	Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC	The First Affiliated Hospital with Nanjing Medical University	Observational	Not yet recruiting	TNBC, Triple Negative Breast Cancer	201	China	clinicaltrials.gov
April 13, 2026	NCT07523529	Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors	Beijing Biotech	Phase 1/2	Recruiting	Advanced Unresectable, Metastatic	72	China	clinicaltrials.gov
April 8, 2026	NCT07517198	Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	Phase 1	Recruiting	Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin...	40	United States	clinicaltrials.gov
April 7, 2026	NCT07513311	A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer	Massachusetts General Hospital	Not applicable	Recruiting	Triple Negative Breast Cancer (TNBC)	75	United States	clinicaltrials.gov
April 6, 2026	NCT07510802	Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC	Beijing Biotech	Phase 1/2	Recruiting	Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer	60	China	clinicaltrials.gov
April 3, 2026	NCT07509515	QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.	Fudan University	Phase 2	Not yet recruiting	Triple-negative Breast Cancer (TNBC)	60		clinicaltrials.gov
March 31, 2026	NCT07503808	A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types	IDEAYA Biosciences	Phase 1	Recruiting	Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal...	150	United States	clinicaltrials.gov
March 27, 2026	NCT07498400	Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer	Xijing Hospital	Not applicable	Active not recruiting	Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer	216	China	clinicaltrials.gov
March 23, 2026	NCT07487519	Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or...	Shanghai Henlius Biotech	Phase 2	Not yet recruiting	Breast Cancer (Triple Negative Breast Cancer (TNBC))	180	China	clinicaltrials.gov
March 20, 2026	NCT07486687	Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab...	The Netherlands Cancer Institute	Phase 3	Not yet recruiting	Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative...	1,000		clinicaltrials.gov
March 20, 2026	NCT07486089	Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)	Beijing Biotech	Phase 1/2	Recruiting	Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)	60	China	clinicaltrials.gov
March 20, 2026	NCT07484776	Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer	Universidad Europea de Madrid	Not applicable	Active not recruiting	Triple-Negative Breast Cancer (TNBC)	40	Spain	clinicaltrials.gov
March 17, 2026	NCT07478705	Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging	Sunnybrook Health Sciences Centre	Not applicable	Not yet recruiting	Triple Negative Breast Cancer, Surveillance, Recurrence, ctDNA	30		clinicaltrials.gov
March 13, 2026	NCT07471815	Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy	Harbin Medical University	Phase 2	Active not recruiting	Breast Cancer Triple Negative Breast Cancer	30	China	clinicaltrials.gov
March 12, 2026	NCT07466303	Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer	Xijing Hospital	Phase 2	Not yet recruiting	Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	84	China	clinicaltrials.gov
March 9, 2026	NCT07458204	Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer	Institut Jean-Godinot	Phase 2	Not yet recruiting	Triple-negative Breast Cancer	760	France	clinicaltrials.gov
March 9, 2026	NCT07458113	Sac-TMT for Active TNBC Brain Metastases	Yale University	Phase 2	Not yet recruiting	Metastatic Triple Negative Breast Cancers	20	United States	clinicaltrials.gov
March 9, 2026	NCT07457359	Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer	Second Affiliated Hospital, Zhejiang University, School of Medicine	Phase 2	Recruiting	TNBC, Triple Negative Breast Cancer	18	China	clinicaltrials.gov
March 2, 2026	NCT07441512	A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced...	Hu Hai	Phase 2	Not yet recruiting	TNBC - Triple-Negative Breast Cancer, TNBC	26		clinicaltrials.gov
February 20, 2026	NCT07423117	A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy	IntoCell, Inc	Phase 1	Enrolling by invitation	Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic...	102	South Korea	clinicaltrials.gov
February 19, 2026	NCT07421479	Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)	Istituti Clinici Scientifici Maugeri SpA	Observational	Active not recruiting	Invasive Breast Cancer	50	Italy	clinicaltrials.gov
February 19, 2026	NCT07419880	Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer	Fudan University	Phase 2	Not yet recruiting	Triple -Negative Breast Cancer	46	China	clinicaltrials.gov
February 17, 2026	NCT07413601	Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in...	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	Not yet recruiting	Triple Negative Breast Cancer Metastatic	78	China	clinicaltrials.gov
February 12, 2026	NCT07407517	Adjuvant Intensification for LAR	Fudan University	Phase 3	Not yet recruiting	Breast Cancer Females, Triple Negative Breast Cancer (TNBC)	904		clinicaltrials.gov
February 10, 2026	NCT07401537	Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast...	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	Recruiting	Triple -Negative Breast Cancer, Breast Cancer	416	China	clinicaltrials.gov
February 6, 2026	NCT07394387	Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.	The First Affiliated Hospital with Nanjing Medical University	Phase 2	Recruiting	Triple Negative Breast Cancer (TNBC)	58	China	clinicaltrials.gov
January 30, 2026	NCT07378306	FMD and Neoadjuvant Chemo-immunotherapy in TNBC	Sun Yat-sen University	Phase 2	Recruiting	Breast Cancer	80	China	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Fudan University	17	October 20, 2026
Tianjin Medical University Cancer Institute and Hospital	6	January 6, 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	5	February 10, 2026
Harbin Medical University	4	August 7, 2026
Xijing Hospital	4	March 27, 2026
Merck Sharp & Dohme LLC	4	May 13, 2025
Istituti Clinici Scientifici Maugeri SpA	3	September 8, 2026
Novartis Pharmaceuticals	3	September 3, 2026
City of Hope Medical Center	3	August 3, 2026
National Cancer Institute (NCI)	3	June 2, 2026
Beijing Biotech	3	April 13, 2026
Yale University	3	March 9, 2026
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	3	February 17, 2026
Sun Yat-sen University	3	January 30, 2026
UNC Lineberger Comprehensive Cancer Center	3	January 14, 2026
Henan Cancer Hospital	3	December 2, 2025
Peking University Cancer Hospital & Institute	3	July 1, 2025
Washington University School of Medicine	2	November 3, 2026
Shanghai Junshi Bioscience Co., Ltd.	2	October 15, 2026
Assistance Publique - Hôpitaux de Paris	2	September 22, 2026

By phase

Phase	New trials	Latest
Phase 2	87	November 3, 2026
Observational	38	October 19, 2026
Phase 1	33	October 26, 2026
Phase 1/2	27	October 27, 2026
Not applicable	27	October 21, 2026
Phase 3	18	October 19, 2026
Phase 2/3	3	April 22, 2026
Early phase 1	2	June 26, 2026
Phase 4	1	April 10, 2025

By country

Country	New trials	Latest
United States	77	November 3, 2026
China	74	October 19, 2026
France	16	October 21, 2026
Australia	13	September 3, 2026
Italy	11	September 8, 2026
Canada	11	July 13, 2026
South Korea	10	April 13, 2026
Japan	8	September 3, 2026
Spain	8	March 20, 2026
United Kingdom	6	April 27, 2026
Israel	6	January 8, 2026
Germany	6	December 3, 2025
Colombia	4	October 2, 2026
Greece	4	September 15, 2026
Singapore	4	July 2, 2026
Portugal	4	May 13, 2025
New Zealand	3	June 26, 2026
South Africa	3	June 26, 2026
Denmark	3	June 5, 2026
Argentina	3	May 13, 2025
Belgium	3	May 13, 2025
Brazil	3	May 13, 2025
Chile	3	May 13, 2025
Poland	3	May 13, 2025
Romania	3	May 13, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.